In January 2019, the decision of the World Health Organization (WHO) Collaborating Center for Drug Statistics Methodology, dated November 21, 2018, on the inclusion of imidazolyl ethanamide pentandioic acid (the active ingredient of the drug Ingavirin®) in the international drug classification system and the assignment of the code ATX-J05AX21, Other Antiviral Drugs, included in group J05A, Antiviral Drugs of Direct Action, came into force1.
The inclusion of Ingavirin® in this group is based on the drug’s antiviral activity and pronounced therapeutic efficacy. Ingavirin® provides early detection of infection and the formation of the antiviral status of cells that stop the reproduction and spread of the virus in the body2.
Due to its unique mode of action, Ingavirin® is active against various groups of respiratory viruses. The drug is effective against influenza A and B viruses, adenovirus, parainfluenza virus, respiratory syncytial virus, coronavirus, metapneumovirus, enterovirus, including Coxsackie virus and rhinovirus3.
Ingavirin® is a new generation antiviral drug for the treatment and prevention of influenza and ARVI of non-influenza etiology with a unique mode of action3. Ministry of Health of the Russian Federation included it in the list of vital and essential drugs (VED) and the minimum range of medications and required drugs.
Ingavirin® is available in capsule form and two dosage options: 60 mg for children over 7 years old and 90 mg for adults. More information about the drug can be found following the link: http://www.ingavirin.ru/